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Novel MOF-based polymer nanocomposite films were successfully prepared using Zr-
based UiO-67 as a metal-organic framework (MOF) and polyurethane (PU) as a 
polymeric matrix. Synchrotron X-ray powder diffraction (SXRPD) analysis confirms the 
improved stability of the UiO-67 embedded nanocrystals and scanning electron 
microscopy images confirm their homogeneous distribution (average crystal size ~ 100-
200 nm) within the 50-m thick film. Accessibility to the inner porous structure of the 
embedded MOFs was completely suppressed for N2 at cryogenic temperatures. 
However, ethylene adsorption measurements at 25ºC confirm that at least 45% of the 
MOF crystals are fully accessible for gas phase adsorption of non-polar molecules. 
Although this partial blockage limits the adsorption performance of the embedded 
MOFs for ocular drugs (e.g., brimonidine tartrate) compared to the pure MOF, an almost 
60-fold improvement in the adsorption capacity was observed for PU matrix after 
incorporation of the UiO-67 nanocrystals. UiO-67@PU nanocomposite exhibits a 
prolonged release of brimonidine (up to 14 days were quantified). Finally, the combined 
use of SXRPD, thermogravimetric analysis (TGA) and FTIR analysis confirmed the 
presence of the drug in the nanocomposite film, the stability of the MOF framework and 
the drug upon loading, and the presence of brimonidine in an amorphous phase once 
adsorbed. These results open the gate towards the application of these polymeric 
nanocomposite films for drug delivery in optical therapeutics, either as a component of 
contact lens, in the composition of lacrimal stoppers (e.g., punctal plugs) or in sub-tenon 
inserts.         
Keywords:
Brimonidine, MOFs, polyurethane, ocular plugs, drug delivery.
Supporting Information. Physicochemical characterization of the synthesized samples 
(synchrotron X-ray powder diffraction, TGA profiles and gas adsorption measurements), 
adsorption kinetics for brimonidine and mathematical models applied are included in 
the Supporting Information.
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Glaucoma is a pathological eye disorder associated with an increase in the intraocular 
pressure (IOP) and one of the leading causes of irreversible blindness worldwide.1 
Approximately, 70 millions middle-aged people and elderly are affected by its common 
form, open angle glaucoma whereof 10% ends in bilateral blindness.2 Among the 
different drugs to treat glaucoma, brimonidine tartrate is one of the most widely 
applied. Brimonidine is an alpha-adrenergic agonist able to reduce the ocular pressure 
through the constriction in the blood vessels, ending in the decrease of the aqueous 
humour production.3 
Conventional drug delivery systems such as eye droplets represent 90% of the marketed 
ophthalmic formulations.4,5 However, severe constrains are associated with this topical 
approach such as tear turnover, fast nasolacrimal drainage and reflex blinking, thus 
ending in a non-optimal dosage.6 Roughly, only 5% of the drug applied topically reaches 
the deeper ocular tissues, thus forcing pharmaceutical producers to increase the drug 
concentration, with the associated increase in the toxicity and, indirectly, the risk of side 
effects.7 Another limitation of these topical administration routes is the low compliance 
of patients, mainly elderly, to strictly follow the administration protocol (administration 
of a number of droplets several times per day).
The development of more efficient ocular drug delivery systems with well-designed and 
prolonged release kinetics remains a challenge in materials science and ophthalmology. 
Nanocarriers such as polyacrylic acid nanoparticles,8 chitosan nanoparticles,9 nano-
vesicles,10 and layered double hydroxides (LDH)11 have been reported as promising 
alternatives for topical brimonidine dosage. However, the main limitation of some of 
these materials for potential application falls in the physical (low gravimetric capacity 
for the drug) and textural properties. 
Novel drug administration platforms to treat ocular disorders prepared from polymeric 
materials (solid or semi-solid inserts) have gained a large popularity in the last few years. 
12–14 The potential advantage of these polymeric devices is the accurate dosing, 
increased ocular residence time, reduction of systemic side effects or better patient 
compliance, just to mention some.15 Due to the potential of these devices in ocular drug 
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delivery, several companies have patented and commercialized them. For instance, one 
of the first marketed ocular insert has been commercialized by Alza (Vacville, CA) as 
Ocusert® which are used to dose anti-glaucoma drug pilocarpine for a maximum of 5-7 
days.16,17 Although these are excellent numbers, the absence of a well-defined regular 
3D network within these polymeric matrices limits their total drug uptake and hinders a 
controlled release. 
Based on these premises, the design of novel functional ocular polymeric devices 
through the incorporation of perfectly designed high-capacity nanofillers would be a key 
stepping stone to increase the versatility and impact of these inserts in nanomedicine. 
A potential approach not widely explored in the literature could be the incorporation of 
nanocarriers with an improved drug adsorption uptake and controlled release, provided 
that the incorporated guest structures does not alter the mechanical properties of the 
insert, while the porous structure of the nanofiller remains fully accessible in the mixed 
formulation. 18–20 Among the potential candidates, high-surface area porous materials 
such as metal-organic frameworks (MOFs) provide an avenue to achieve these 
requirements.21 MOFs are crystalline materials formed by the union of metal centres 
and organic likers. The self-assembly of metal clusters (or nodes) and organic ligands 
allows the design of a large number of 1D to 3D networks characterized by high surface 
area, a large pore volume and tuneable host-guest interactions.22 Over the last few 
years, these materials have shown promise as a potential platform for drug delivery in 
powder form.23,24 Recent studies from Gandara-Loe et al. have shown that MOFs can 
store a large amount of brimonidine tartrate (up to 600 mg of drug per gram of MOF), 
and with an extended release time of up to 12 days, in the specific case of UiO-67. 
Furthermore, in vitro cytotoxicity assays have demonstrated the low toxicity of UiO-67 
for retinal photoreceptor cells.25 The excellent performance of UiO-67 is motivated by 
the presence of large tetrahedral and octahedral cages in the micro/mesoporous 
range.26 Taking into account these excellent properties, the successful incorporation of 
these 3D porous networks in continuous polymeric matrices will offer a new perspective 
in nanomedicine with more suitable nanocomposite materials (instead of working with 
powders), with novel functionalities (e.g., drug delivery properties), to be used either as 
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micro-inserts (e.g. punctal plug in lacrimal or sub-tenon cavities) or as a component in 
contact lens. 27,28
Polymer-MOF nanocomposite materials have already been reported in the literature as 
potential candidates for gas adsorption/separation processes such as, CO2/N2 or 
CO2/CH4 separation or ethylene adsorption.29,30 There are recent studies on the use of 
HKUST-1/polyurethane nanocomposite membranes for drug encapsulation and 
controlled release.31 However, the understanding of molecular accessibility in liquid 
phase adsorption processes is still a challenge due to the different nature of the 
polymeric network and the MOF nanofiller. To the best of our knowledge, polymer-
MOFs nanocomposite films have not yet been tested as a drug delivery carrier for ocular 
therapeutics. 
Based on these premises, the main goal of this work is to report an optimal synthesis of 
functional MOF-based polyurethane thin films, and to evaluate the performance of 
these UiO-67@PU nanocomposites for brimonidine adsorption/release in liquid phase. 
The successful development of these functional materials (MOF@polymer) will open the 
gate towards the application of these devices in a number of ocular disorders that 
require a controlled and prolonged release of drugs, from glaucoma treatment to post-
surgical treatments by anti-inflammatory drugs.
2. Experimental section
2.1. UiO-67 synthesis
UiO-67 was synthetized based on the procedure reported in the literature by Katz et al.32 
Briefly, 0.268 g of ZrCl4 were dissolved in a mixture of 20 mL of N,N-dimethylformamide 
(DMF) and 2 mL of concentrated HCl. In a second vessel 0.360 g of 4,4’-
biphenyldicarboxylic acid (BDPC) were dissolved in 40 mL of DMF. The two solutions 
were mixed and maintained under sonication for 30 min. The final solution was 
transferred to a 200 mL glass jar, closed tightly and kept at 80ºC overnight. The resulting 
white solid was filtered and washed first with DMF (2x30 mL) and then with ethanol 
(2x30 mL). The sample was activated first under low vacuum conditions (13×10-3 Pa) up 
to 90ºC and, afterwards, at 150ºC for 3 h under ultra-high vacuum conditions.
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The UiO-67@PU nanocomposite films were fabricated by following the procedures 
described below. Polyurethane (PU) solution was prepared by dissolving poly [4,4’-
methylenebis (phenyl isocyanate)-alt-1,4-butanediol/di(propylene 
glycol)/polyurethane] pellets (purchased from Sigma Aldrich and used without further 
alterations) in tetrahydrofuran (THF) for 24-48 hours until complete dissolution of the 
polymer pellets. 30 wt.% UiO-67@PU nanocomposites and pristine PU films were 
produced by the dispersion of a specified amount of previously synthesized MOF 
particles (of a required wt.%) in a small amount of THF (930 mg of MOF per 1 mL of THF) 
before their incorporation into the PU-THF solution. The dispersion was performed by a 
combination of sonication (5 min) and magnetic stirring (20 min, 80 rpm). This strategy, 
followed by Cohen et al. 33, has proven to be a versatile approach for the preparation of 
homogeneous polymer-MOF nanocomposites. The thin films were subsequently cast 
onto a glass substrate via the doctor blade technique using a casting speed of 10 mm/s 
to achieve membranes of ~50 μm in thickness.30,34
2.3. Synchrotron X-ray powder diffraction (SXRPD) analysis
Synchrotron X-ray powder diffraction data (SXRPD) were collected on the powder 
diffraction end station of the MSPD beamline at synchrotron ALBA in Spain, using a 
MYTHEN detector and a wavelength of 0.4227 Å. The experiments were performed in 
an ad hoc capillary reaction cell (fused silica capillary, inner diameter 0.7 mm, outer 
diameter 0.85 mm). SXRPD measurements were performed at 25ºC to the as-
synthesized UiO-67, PU and the UiO-67@PU films, and also to the UiO-67@PU films after 
brimonidine adsorption. The reference spectra for brimonidine tartrate powder was also 
determined. 
2.4. Thermogravimetric analysis (TGA) 
Thermogravimetric analysis data of UiO-67, PU film and UiO-67@PU film were obtained 
using TG-DTA METTLER TOLEDO equipment model TG/SDTA851e/SF/1100. The samples 
were measured using an alumina sample holder and temperature range of 25ºC-600ºC 
with a heating rate of 5 ºC/min under N2 flow.
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2.5. Scanning electron microscopy (SEM) evaluation
Cross-section micrographs were recorded using a Hitachi scanning electron microscope 
model S3000N. This microscope is equipped with Bruker brand X-ray detector (model 
Xflash 3001) for EDS microanalysis and mapping. Samples were kept under cryogenic 
conditions (liquid N2) before the analysis in order to obtain a high-quality cross section 
and avoid surface alterations during the sectioning process.
2.6. Nitrogen and ethylene adsorption/desorption isotherms
Textural properties and gas phase accessibility of the different samples were evaluated 
by gas physisorption, i.e. nitrogen adsorption at -196ºC and ethylene adsorption at 25ºC. 
Nitrogen gas adsorption measurements were performed in a homemade fully 
automated manometric equipment designed and constructed by the Advanced 
Materials Group (LMA), now commercialized as N2GSorb-6 (Gas to Materials 
Technologies, www.g2mtech.com). Nitrogen adsorption data were used to calculate a) 
the total pore volume (Vt) at relative pressure of 0.95, b) the BET surface area (SBET) and 
c) the micropore volume (VN2), after application of the Dubinin-Radushkevich (DR) 
equation. Ethylene adsorption experiments were performed in a home-built fully 
automated manometric equipment, now commercialized by Quantachrome Corp. as 
VSTAR. Before the experiments, samples were degassed at 100ºC for 8 h under high 
vacuum conditions (10-5 torr).
2.7. Loading and release experiments
Brimonidine tartrate quantification was done based on the High Performance Liquid 
Chromatography method developed by Karamanos et al.35 A stock solution of 1500 ppm 
of brimonidine tartrate was prepared by dissolving 1.5 g in 1000 mL of ultrapure water. 
Calibration curve was constructed by measuring concentrations from 2 to 15 ppm using 
chromatographic conditions, analytical column Supelcosil LC-18, 5 µm, 250 x 4.6 mm i.d. 
stainless steel (Supelco, Bellfonte, PA, USA) equipped with RP-18 precolumn, 20 x 4.6 
mm i.d. (Supelco). The mobile phase was a mixture 9:1 (v/v) of 10 mM triethylamine pH 
3.2 buffer and acetonitrile. The separation was performed at room temperature, at a 
flow rate of 1.0 mL/min, injection volume of 20 µL, and the detection of the brimonidine 
at 248 nm.
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2.7.1. Brimonidine loading experiments
Brimonidine adsorption isotherms were performed at 25ºC using a group of aqueous 
solution (pH = 7) prepared from the stock solution with an initial concentration of 250 
ppm, 500 ppm, 750 ppm, 1000 ppm and 1500 ppm of brimonidine tartrate. The 
nanocomposite films were degassed at 100ºC overnight before the experiment. 
Approximately 100 mg of film were placed in contact with 50 mL of solution at each of 
the concentrations described above and left under stirring until equilibrium was 
reached. Aliquots were taken at different time intervals in order to evaluate the 
adsorption kinetics of the films.
The quantification of brimonidine was determined using High Performance Liquid 
Chromatography (HPLC) by diluting each aliquot 1:100 and using the method described 
above. 
2.7.2. Brimonidine release experiments
100 mg of UiO-67@PU film, previously degassed, was loaded with brimonidine by 
contacting it with 50 mL of a 1500 ppm brimonidine tartrate aqueous solution. The 
system was left at 25ºC under stirring for 24 h to ensure full equilibrium. After this time 
the film was separated from the solution and an aliquot was taken to determine the 
maximum loading amount. The brimonidine-loaded film was washed several times with 
ultrapure water and dried under vacuum at 60ºC for 6 h. The dried brimonidine loaded 
film was immersed in 50 mL of physiological solution (PBS) and aliquots were taken at 
different times up to 14 days. The aliquots were diluted 1:100 and brimonidine 
quantification was performed using the HPLC method described above.
3. Results and discussion
3.1. Characterization of the synthesized films and accessibility of the embedded 
MOFs
The crystallinity of the synthesized materials has been evaluated through synchrotron 
X-ray powder diffraction measurements (SXRPD). Figure 1 shows the comparative 
SXRPD patterns for the as-synthesized UiO-67 crystals, obtained by solvothermal 
method, and the UiO-67@PU film. The SXRPD pattern of the UiO-67 sample perfectly 
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fits with the simulated pattern and with those previously described in the literature, 
thus confirming the quality and reproducibility of the synthetized MOF.32 Concerning 
the UiO-67@PU nanocomposite material, the SXRPD pattern confirms the presence of 
a semi-crystalline system, with the combination of crystallinity due to UiO-67 
nanoparticles and the amorphous background from the PU matrix. The PU matrix is 
characterized by a broad peak between 2𝜃 = 6º – 10º (see Figure S1), whereas the main 
diffraction peaks of the MOF can be clearly appreciated at 2𝜃 = 2.3º-2.6º. These results 
confirm the preservation of the 3D network in the UiO-67 nanocrystals upon 
incorporation in the polymeric matrix, and their excellent crystallinity. 
Figure 1. Synchrotron XRPD experimental patterns of UiO-67 and UiO-67@PU film 
accompanied by simulated pattern of UiO-67. 
Morphologically, UiO-67@PU film is a semi-transparent and flexible composite material 
(Figure S2) with high versatility for the production of different ocular devices. As it is 
shown in Figure 2, the nanocomposite film is formed by MOF nanocrystals (average 
crystal size 100-200 nm) embedded into the polyurethane matrix, giving a film of 
approximately 50 µm thick. Figure 2c shows the relatively uniform distribution of the 
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UiO-67 nanocrystals within the PU matrix, an observation that was further confirmed by 
specific Zr-mapping experiments (Figure 2d). Previous results described in the literature 
for gas separation using similar composites have anticipated that the accessibility 
(permeation of gases) decreases with the thickness of the film.34,36 Based on this 
assumption and taking into account the objectives of this study (liquid phase adsorption 
processes usually possess lower kinetics compared to gas adsorption processes), we 
assume that a film of 50 µm can be considered as a good approach. Furthermore, 30 
wt.% MOF loading can be considered as an upper limit to keep a good balance between 
thermomechanical and toughness properties for a potential future application.34,37 
Figure 2. SEM micrograph of (a) as-synthesized UiO-67 nanocrystals, (b) cross-section 
of a 50 µm thick neat PU film, (c) cross-section of UiO-67@PU 50-µm film and (d) Zr 
EDX mapping (green colour) of a cross-section of UiO-67@PU nanocomposite film.
Thermogravimetric (TGA) analyses were used to evaluate the thermal stability of the 
nanocomposite film compared to the pure components (PU and UiO-67). Polyurethane 
and UiO-67 nanoparticles exhibit characteristic decomposition profiles with very sharp 
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PU film exhibits a decomposition profile with a well-defined decomposition peak 
centred at 337ºC and a small shoulder at 430ºC, which is typical of polyurethane 
materials.38 In the case of UiO-67, the TGA profile shows the release of the solvent at 
135ºC and the main framework decomposition close to 550 ºC.26 Figure 3 also shows 
the TGA profile for the UiO-67@PU nanocomposite film. In this case the scenario is more 
complex. As it can be appreciated, the nanocomposite material exhibits a broad 
decomposition profile with a main peak located in between 200 ºC and 300 ºC. 
Interestingly, this peak is not symmetric and clear shoulders can be appreciated at 
around 217ºC and 278ºC, in addition to the main contribution at 252ºC. Taking into 
account that 70 wt.% of the composite corresponds to PU, the main contribution at 
252ºC must be attributed to the decomposition of the polymeric matrix. Compared to 
the pure polymer (ca. 337ºC), these results indicate a clear shift to lower temperatures 
upon incorporation of the MOF nanofillers, in close agreement with previous studies 
reported in the literature.34 Apparently, the incorporation of the MOF nanocrystals 
limits the cross-linking between PU molecular chains, thus reducing their thermal 
stability. For the sake of clarity, a deconvolution of the DTGA profile for the 
nanocomposite system can be seen in Figure S3. In addition to the decomposition of the 
polymeric matrix, the aforementioned shoulders must be attributed to solvent removal 
(ca. 217ºC) and to the secondary contribution in the decomposition of the PU matrix 
(ca. 278ºC). Furthermore, the nanocomposite material exhibits an additional 
decomposition peak at 528ºC, unambiguously attributed to the degradation of the 
embedded MOF. This finding constitutes another proof about the successful 
incorporation of the MOF crystals in the polymeric matrix. Table S1 contains a summary 
of the TGA results for the three samples evaluated.  
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Figure 3. Thermogravimetric analysis (TGA and DTGA) of PU, UiO-67 and UiO-67@PU 
film.
To check the accessibility of the 3D porous network in UiO-67@PU nanocomposite films 
to gas molecules, the nitrogen adsorption/desorption isotherm was performed at -
196ºC and compared to that of the pure MOF. As it can be appreciated in Figure S4, UiO-
67 presents the typical adsorption-desorption isotherm already described elsewhere,32 
with a large uptake at low relative pressures due to its highly microporous framework, 
and the associated step at p/p0  0.15 attributed to the presence of wider pores (small 
mesopores). This observation is in close agreement with the presence of two kind of 
cavities in UiO-67, tetrahedral and octahedral cages with a diameter of 1.1 and 2.3 nm, 
respectively. 32  Interestingly, in the specific case of the UiO-67@PU film the accessibility 
for nitrogen at cryogenic temperatures is completely suppressed over the whole relative 
pressure range evaluated. This observation is in close agreement with previous studies 
described in the literature for ZIF-8 and ZIF-7 loaded polymeric matrices.37 Apparently, 
nitrogen with a quadrupolar moment is not able to diffuse through the rubbery 
polymeric network at cryogenic temperatures. Despite the inaccessibility of nitrogen to 
the embedded MOF crystals, this observation does not necessarily reflect the real 
Page 13 of 28
ACS Paragon Plus Environment





























































scenario in the composite material. Based on our previous experience, adsorption of 
non-polar molecules (for instance, hydrocarbons) constitutes a complementary tool to 
evaluate the porous structure in these MOF@polymer nanocomposites. Figure 4 shows 
the ethylene adsorption/desorption isotherms at 25ºC for the pure PU, UiO-67 and the 
nanocomposite. These results show that, contrary to N2, ethylene is indeed able to 
access the inner porous structure in this kind of materials. Whereas the pure PU film 
exhibits an adsorption capacity close to 0 mmol/g, UiO-67 nanoparticles are able to 
adsorb up to 1.31 mmol/g at a pressure of 1 bar. For the UiO-67@PU nanocomposite 
sample, the total adsorption capacity for ethylene at 1 bar is ca. 0.18 mmol/g. After a 
normalization to the total amount of MOF (considering that the composite contains ca. 
30 wt.%), this value scales up to a total uptake of 0.59 mmol/gMOF. Compared to the pure 
UiO-67, this result constitutes a reduction of 55% in the adsorption capacity of the 
embedded crystals, i.e. embedded nanocrystals are indeed accessible to gas molecules, 
although only partially.



























Figure 4. Ethylene adsorption (filled symbol)-desorption (open symbol) isotherms at 
25ºC in as-synthesized UiO-67, PU and UiO-67@PU films.
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3.2. Brimonidine adsorption and release
Brimonidine adsorption isotherms were performed in aqueous media (ultrapure water) 
and at room temperature in order to quantify the maximum amount of drug adsorbed 
in the porous structure of the synthesized films. As is shown in Figure 5, while the 
adsorption in the pure PU film is close to 0 mg/g, the maximum brimonidine adsorption 
capacity in the UiO-67@PU film (at an equilibrium time of 4h; see Figure S5) obtained 
from the Langmuir model achieves a value of 58.4 mg of brimonidine per gram of film, 
i.e. 194.7 mg of brimonidine per gram of UiO-67 (considering the nominal value of 30 
wt.% of UiO-67 in the film). This value differs from that reported in the literature for 
pure UiO-67 nanoparticles (ca. 600 mgbrimonidine/gMOF).25 The reduction in the adsorption 
capacity for the nanocomposite (around 67% reduction) is in close agreement with the 
gas-phase ethylene adsorption measurements described above (ethylene was able to 
access 45% of the porosity whereas brimonidine only 32.5% of the MOF porous 
network). Although these numbers must be optimized, this finding constitutes an 
important development elucidating the potential application of these MOF-doped 
polymeric matrices for liquid-phase adsorption/desorption processes. Even though 
these processes are performed in the presence of a solvent (for instance, an aqueous 
solution), the embedded MOFs are able to preserve a similar accessibility to the target 
molecule (e.g. ocular drug), compared to similar measurements in gas phase, i.e. in the 
absence of solvent. These results suggest that UiO-67 cavities are able to host both 
ethylene (molecular size of 4.7 x 9.8 Å) and brimonidine (3.28 x 4.18 x 4.84 Å) in a similar 
extend.39,40 Compared to the neat PU polymer, the incorporation of UiO-67 nanofillers 
gives rise to a 60-fold increase in the adsorption capacity for brimonidine tartrate. 
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Figure 5. Brimonidine liquid-phase adsorption isotherms in PU and UiO-67@PU films at 
25ºC (C0 = 1500 ppm).
In order to mimic a potential application in human body, brimonidine release isotherms 
were performed in PBS solution at room temperature and neutral pH, Figure 6. As it can 
be observed, the UiO-67@PU nanocomposite exhibits a fast release (up to 7 % of the 
total uptake) in the first minute of the experiment. Afterwards, there is a continuous 
release with time up to a maximum of 10% of the total brimonidine retained after 14 
days exposure. The large release in the first few hours must be attributed to brimonidine 
weakly interacting with the nanocomposite and/or adsorbed in the external 
layers/pores of the film. Considering the traditional topical administration of 
brimonidine, i.e. a patient must take one droplet of brimonidine solution of 2 mg/mL 
(Alphagan P®, Allergan) every 8h, this means 0.3 mg of brimonidine per day or 4.2 mg in 
14 days.7 Taking into account the total uptake of 58.4 mg/g for our composite, a release 
of 10 % (5.8 mg/g) after 14 days is within the needs of a normal patient with glaucoma, 
thus validating our approach. At this point it is important to highlight that we cannot 
exclude the possibility that some brimonidine is already removed/released from the 
loaded film during the washing step performed after the loading and before the release 
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experiment (this washing step was designed to remove exclusively the brimonidine 
retained in the external surface of the film).     


















Figure 6. Brimonidine tartrate release kinetics at 25ºC in physiological media PBS 
(loading concentration 1500 ppm)
At this point, the open questions remain the compatibility of the drug with the 
composite, the stability of the MOF structure after the loading process and finally, the 
potential location of the drug molecule in the composite system. Next sections are 
devoted to answer all these questions. 
3.3. Brimonidine-composite compatibility and stability studies
Structural stability of the MOF framework is an important parameter to be considered 
in liquid-phase adsorption processes. It is widely accepted in the literature that MOF 
materials can exhibit a limited stability in the presence of aqueous environments or after 
the incorporation of the drug.41 In the specific case of UiO-67, it is well-known that upon 
exposure to water or moisture, this system exhibits a large instability due to the 
hydrolysis of the linker-metal bonds, and the associated pore collapse.42–44 However, 
the partial amorphization of the UiO-67 nanoparticles during the adsorption/release of 
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brimonidine has been very useful to extend the released kinetics beyond 12 days, as 
described before by some of us.25 
Figure 7. Scheme of possible scenarios for Brimonidine adsorption in MOF@polymer 
composites: (a) adsorption in the peripheric MOF crystals, (b) fully inaccessible and (c) 
fully accessible embedded MOF nanocrystals.
In addition to the structural stability, another concern is the adsorption mechanism. 
Adsorption of brimonidine into MOF-based polymeric films can be explained via three 
potential scenarios. As summarized in Figure 7, brimonidine can be adsorbed only in 
those MOF crystals located in the periphery of the PU film (option A), brimonidine can 
be adsorbed only in the polymeric matrix, i.e. MOF nanocrystals are completely blocked 
(option B) or it can be adsorbed equally in the different crystals homogenously 
distributed within the PU film (option C). To identify which of these options is the most 
plausible to explain the adsorption mechanism, the UiO-67@PU nanocomposite has 
been thoroughly evaluated before and after adsorption of brimonidine using 
synchrotron X-ray diffraction, thermogravimetry (TGA) and FTIR.
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Figure 8. Synchrotron X-ray powder diffraction patterns of UiO-67@PU film before and 
after being exposed to the brimonidine solution.
Synchrotron X-ray diffraction measurements were performed in order to elucidate the 
structural parameters of the UiO-67 embedded crystals before and after the loading of 
brimonidine. As it can be observed in Figure 8 both patterns are rather similar even after 
exposure to the brimonidine aqueous solution for several days. These results are 
contrary to the performance of the pure MOF (Figure S6), where a significant structural 
deterioration was identified after 1 day in contact with water and confirms the improved 
structural stability of UiO-67 upon encapsulation in the PU matrix. 25
Although the cavities in UiO-67 (octahedral of 2.3 nm and tetrahedral of 1.15 nm) are 
large enough to accommodate the brimonidine molecule, the open question at this 
point is how to ascertain if brimonidine is able to take advantage of these cavities.32 
Synchrotron X-ray diffraction measurements of the pure brimonidine tartrate (Figure 
S7) show a rich XRD pattern with a large number of peaks in the range 2 and 18º, 
confirming the high crystallinity of this molecule. The absence of these peaks in the 
SXRPD pattern of the brimonidine-loaded UiO-67@PU nanocomposite (Figure 8) could 
be a priori an evidence of the absence of brimonidine both in the polymeric network 
and in the embedded MOF nanocrystals. However, this observation would be in 
contradiction with brimonidine adsorption measurements reported in Figure 5. This 
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inconsistency must be explained due to the amorphization of the drug upon adsorption, 
thus explaining the absence of peaks in the SXRPD pattern. This hypothesis would be in 
agreement with the encapsulation of the drug in the MOF cavities, with the associated 
limitation for these molecules to arrange in a periodic fashion. These conclusions are 
also supported by previous studies dealing with the adsorption/release of brimonidine 
through ocular devices suggesting the transformation of crystalline brimonidine into an 
amorphous phase once it is adsorbed into the material.45–47
The unit cell parameters deduced for the embedded UiO-67 crystals after Rietveld 
refinement are summarized in Table 1. Pure UiO-67 crystals have a cubic unit cell with 
lattice parameters a = b = c = 26.8447(9) Å. As it can be observed, the lattice parameters 
remain rather similar after incorporation of the UiO-67 crystals in the polymeric matrix, 
in close agreement with the high quality of the crystals described in Figure 1. 
Interestingly, lattice parameters do not change after exposure of the UiO-67@PU 
nanocomposite to an aqueous solution of brimonidine. Although these results confirm 
the large stability of UiO-67 nanocrystals in an aqueous environment upon incorporation 
in the PU matrix, these are not conclusive about the location of brimonidine upon 
adsorption. Unfortunately, Rietveld refinement analysis of the embedded crystals does 
not allow to answer this question due to the limited quality of the SXRPD pattern. 
Table 1. Summary of structural parameters and adsorption performance of UiO-67, and 
UiO-67@PU film before and after loading with brimonidine.
UiO-67 UiO-67@PU UiO-67@PU-BRI
Cell parameter a  (Å) 26.8447(9) 26.8306(6) 26.8252(6)
SBET (cc STP/g) 3352 0 ----
Ethylene adsorption (mmol/g) 1.31 0.18 ----
Brimonidine adsorption (mg/g) 60025 58.4 ----
Brimonidine release (%) 50% (12 days) 10% (14 days) ----
To further ascertain the adsorption mechanism, TGA analysis was performed in the UiO-
67@PU film after the loading of brimonidine. For clarity, the TGA of pure brimonidine 
tartrate has been included in Figure S8. Brimonidine tartrate exhibits a single 
decomposition peak at around 210 ºC. A closer look to the TGA profile for the 
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brimonidine-loaded UiO-67@PU nanocomposite (Figure S9) shows that the TGA peaks 
corresponding to the decomposition of the PU matrix and the UiO-67 crystals are shifted 
to higher temperatures upon adsorption. In addition, the thermogram shows an 
additional tiny peak at 210ºC, not present in the un-loaded UiO-67@PU material, that 
can be attributed to brimonidine within the composite film (blue peak deconvoluted in 
Figure S10). Although the shifts observed in Figure S9 for the decomposition of PU and 
UiO-67 upon brimonidine adsorption could be an indication of the presence of 
brimonidine in both domains, the real location of the drug remains still an open 
question. Last but not least, it is important to highlight that the quantification of the 
tinny peak at 210ºC corresponds to ~ 23 mg Brimonidine/gcomposite film. Although this is a 
rough estimation, we cannot exclude that around 40% of the brimonidine loaded at 
1500 ppm (Figure 5) could be lost during the washing step applied before the TGA 
analysis. A similar hypothesis could be used to explain the low release achieved in Figure 
6. 
Finally, the presence of the drug has been evaluated using FTIR of the UiO-67@PU film 
before and after loading with brimonidine, Figure 9. The FTIR spectra for the individual 
components have also been included for clarity. As it can be observed, before loading, 
the FTIR spectra of the UiO-67@PU film shows the characteristic peaks of PU and UiO-
67. PU has a characteristic peak at 3329 cm-1 attributed to the stretching of the NH bond 
(Figure 9a). In addition there are two contributions at 1724 cm-1 and 1696 cm-1 due to 
the poly(caprolactone) ester bond, and the -CH stretching vibration at 2944 cm-1, among 
others.48,49 The characteristic peaks of UiO-67 can be observed at 1594 cm-1, 1528 cm-1 
and 1411 cm-1 due to the stretching vibrations of the carboxylate group of the ligands 
and, the peaks at 815 cm-1, 766 cm-1 and 652 cm-1 due to the Zr-O stretching 
vibrations.50,51
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Figure 9. FTIR spectra of (a) UiO-67 (bottom), PU (middle) and UiO67@PU film (upper), 
and (b) UiO67@PU film before (bottom) and after (upper) loading with brimonidine.
As already reported in the literature, brimonidine tartrate also presents characteristic 
vibrations in the IR range. These characteristic vibrations include peaks at 3212 and 3268 
cm-1 owing to N-H stretching vibration from the secondary amine groups (RR’-NH). Peaks 
around 1650 cm-1 are attributed to C=O stretching and -CN stretching appears at 1284 
cm-1.52–54 
The most remarkable feature of the FTIR spectra of UiO-67@PU after loading 
brimonidine is, in addition to the bands described above due to PU and UiO-67, the 
presence of a wide contribution around 3575-3074 cm-1. This broad contribution could 
be associated to the overlapping of signals from adsorbed H2O (O-H stretching at 3404 
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cm-1), and to the stretching -NH vibrations characteristics of urea and urethane bonds 
(3333 cm-1) in PU.48,49 However, taking into account that the brimonidine-loaded sample 
has been vacuum dried at 60ºC before the FTIR spectra, and the absence of this wide 
contribution in the drug-free nanocomposite film, the presence of this broad 
contribution must be unambiguously attributed to the presence of brimonidine 
chemically interacting with the composite via hydrogen bonding with surface oxygen 
and nitrogen groups. This finding is supported by the presence of a new peak at 1650 
cm-1 (solid line in Figure 9b) in the loaded film due to the C=O groups of the brimonidine 
tartrate. These assignments are in perfect agreement with previous studies in NH2-MIL-
88(Fe) loaded with brimonidine.53 In summary, FTIR spectra clearly confirm the presence 
of the drug in the UiO-67@PU film, although the real location, either in the polymeric 
matrix or in the UiO-67 network cannot be easily identified.  
Conclusions
We have successfully developed a novel UiO-67-based polyurethane film with an 
excellent adsorption/release performance for an ocular drug such as brimonidine 
tartrate. Synchrotron X-ray powder diffraction measurements confirms the high quality 
of the MOF nanocrystals when embedded in a hydrophobic polymer such as PU and 
their improved stability in an aqueous environment, compared to the pure MOF. 
Although the inner porous structure is not accessible to nitrogen with a quadrupole 
moment, this is not the case for the adsorption of non-polar molecules (e.g., 
hydrocarbons) at room temperature. Although the partial accessibility of the embedded 
MOFs limits the brimonidine adsorption performance, the UiO-67@PU composite gives 
rise to a 60-fold improvement compared to the neat PU film. Synchrotron XRPD, TGA 
and FTIR measurements of the composite before and after loading brimonidine confirm 
the presence of the drug within the UiO-67@PU film, although the real role of the 
polymer matrix and the UiO-67 nanocrystals cannot be conclusively confirmed. The total 
brimonidine uptake of the composite is as high as 58.4 mgBRI per gram of composite or 
194.7 mgBRI per gram of MOF. These results in liquid-phase are highly promising and 
open the door to the design of novel polymeric inserts with functional properties and 
improved performance (for instance with drug delivery properties), to be applied in a 
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number of ophthalmological disorders, either as a component of contact lens, in the 
composition of lacrimal stoppers (e.g., punctal plugs) or in sub-tenon inserts.         
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